Tonghua Dongbao third generation insulin analogue aspart insulin injection obtained the approval of clinical trial

Aspartic insulin is the third generation of insulin treatment drug, which belongs to insulin analogue This is the second insulin analogue obtained by Tonghua Dongbao after last year's clinical application of glargine insulin After that, the company is expected to apply for clinical insulin and insulin, which will become the most listed company applying for insulin clinical new drugs in China At present, Tonghua Dongbao mainly uses second-generation insulin as its main product, which accounts for about 80% of the company's revenue, becoming one of the largest biopharmaceutical companies in China The reporter noted that in 2013, the company achieved nearly 800 million yuan of insulin revenue If the company achieved the minimum target of equity incentive growth of 35% in 2014, the company's 2014 insulin sales revenue should be more than 1 billion yuan Compared with the annual average growth rate of about 20% in the previous years, it is obviously accelerated If the company wants to realize the equity incentive plan in 2015 and 2016, its growth rate will maintain this level While adhering to the development direction of protein medicine, Xiamen Tebo, which holds more than 34% of the shares of Tonghua Dongbao, has made continuous breakthroughs in clinical aspects Its long-acting interferon alfa-2a has been listed as a major new drug development project in the 12th Five Year Plan It is currently in the stage of completing clinical production approval, and is a heavy drug for the treatment and prevention of hepatitis C In addition, several biopharmaceuticals, such as Y-type peg recombinant human interferon A2B injection (class I), Y-type peg recombinant human granulocyte factor injection (class I), are also in clinical use.